DelistingJul 17, 2026, 04:36 PM
Actuate Therapeutics Receives Nasdaq Delisting Notice for MVLS
AI Summary
Actuate Therapeutics, Inc. received a notice from Nasdaq on July 15, 2026, indicating non-compliance with the Market Value of Listed Securities (MVLS) requirement. The company's MVLS was below the $50 million minimum for continued listing on The Nasdaq Global Market. Actuate Therapeutics has 180 calendar days, until January 11, 2027, to regain compliance and intends to take all reasonable measures to do so.
Key Highlights
- Received Nasdaq notice on July 15, 2026, regarding non-compliance.
- Market Value of Listed Securities (MVLS) was below $50 million minimum.
- Non-compliant with Nasdaq Listing Rule 5450(b)(2)(A).
- Has 180 calendar days, until January 11, 2027, to regain compliance.
- Company intends to monitor MVLS and take reasonable measures.
- May appeal delisting or transfer to Nasdaq Capital Market if non-compliant.
Price Impact
More from ACTU